GSK Braces For Impact: Advair Generic Could Reduce US Brand To £1Bn
Executive Summary
Although it’s not yet clear if an interchangeable version of the respiratory blockbuster will be approved by FDA, CEO Andrew Witty prepared investors to expect a hit, forecasting that a mid-year launch could significantly reduce revenues.
You may also be interested in...
Teva AirDuo Poised To Be A Discounted, But Not Interchangeable, Version Of Advair
FDA approved Teva’s AirDuo RespiClick, which contains the active ingredients in GlaxoSmithKline’s Advair, but in the RespiClick device, which means it will not be an interchangeable generic.
GSK US Pharma President Jack Bailey On A “Dynamic” 2017
With new US President Trump in place, new corporate CEO Walmsley to take the reins in April and the opportunity for four US drug launches in 2017, GSK’s president of US Pharmaceuticals says he is preparing for an “intense” year.
Advair: A Big Generic Opportunity And A Big Question Mark In 2017
Takeda’s Velcade, Pfizer’s Viagra and Gilead’s Viread are among the brand drugs expected to face generic competition in the US for the first time in 2017. One unknown is if FDA will approve Mylan’s or Hikma’s ANDAs for a generic version of GSK’s Advair.